Therapeutic Asset Ratings

1,583 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
FENTANYL Mastectomy	Xiaguang Duan	Early P1	CC (41)
FMISO BCLC Stage a Hepatocellular Carcinoma	Emory University	Early P1	CC (41)
GADOTERIDOL Multiple Sclerosis	University of Utah	Early P1	CC (41)
Gly-Low Cardiovascular Diseases	Hoskinson Health and Wellness Clinic	Early P1	CC (41)
Gly-Low Cognitive Impairment	Hoskinson Health and Wellness Clinic	Early P1	CC (41)
Gly-Low Hypertension	Hoskinson Health and Wellness Clinic	Early P1	CC (41)
Gly-Low Inflammation	Hoskinson Health and Wellness Clinic	Early P1	CC (41)
PITAVASTATIN Recurrent Glioblastoma	C.Dirven	Early P1	CC (41)
rd13-02 cell infusion Neoplasms	Kai Lin Xu，MD	Early P1	CC (41)
Zirconium Zr 89 Crefmirlimab Berdoxam Melanoma (Skin)	Abramson Cancer Center at Penn Medicine	Early P1	CC (41)
PROPRANOLOL Obesity	University of Missouri-Columbia	Early P1	CC (40)
111in-abd147 Castration Resistant Prostate Cancer	Thomas Hope	Early P1	C (39)
111in-abd147 Neuroendocrine (NE) Tumors	Thomas Hope	Early P1	C (39)
11C-HY-2-15 Tauopathies	University of Pennsylvania	Early P1	C (39)
11C-M503 Tauopathies	University of Pennsylvania	Early P1	C (39)
[11c]modag-005 Healthy Adult Participants	MODAG GmbH	Early P1	C (39)
[11c]modag-005 MSA - Multiple System Atrophy	MODAG GmbH	Early P1	C (39)
[11c]modag-005 Parkinson Disease (PD)	MODAG GmbH	Early P1	C (39)
1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIACETIC ACID, 10-(2-(((4-(((3-((2R,5S,8S,14R)-5-(3-((AMINOIMINOMETHYL)AMINO)PROPYL)-14-((4-HYDROXYPHENYL)METHYL)-1-METHYL-8-(2-NAPHTHALENYLMETHYL)-3,6,9,12,15-PENTAOXO-1,4,7,10,13-PENTAAZACYCLOPENTADEC-2-YL)PROPYL)AMINO)CARBONYL)PHENYL)METHYL)AMINO)-2-OXOETHYL)- Erdheim-Chester Disease	Memorial Sloan Kettering Cancer Center	Early P1	C (39)
1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIACETIC ACID, 10-(2-(((4-(((3-((2R,5S,8S,14R)-5-(3-((AMINOIMINOMETHYL)AMINO)PROPYL)-14-((4-HYDROXYPHENYL)METHYL)-1-METHYL-8-(2-NAPHTHALENYLMETHYL)-3,6,9,12,15-PENTAOXO-1,4,7,10,13-PENTAAZACYCLOPENTADEC-2-YL)PROPYL)AMINO)CARBONYL)PHENYL)METHYL)AMINO)-2-OXOETHYL)- Histiocytic Neoplasms	Memorial Sloan Kettering Cancer Center	Early P1	C (39)
1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIACETIC ACID, 10-(2-(((4-(((3-((2R,5S,8S,14R)-5-(3-((AMINOIMINOMETHYL)AMINO)PROPYL)-14-((4-HYDROXYPHENYL)METHYL)-1-METHYL-8-(2-NAPHTHALENYLMETHYL)-3,6,9,12,15-PENTAOXO-1,4,7,10,13-PENTAAZACYCLOPENTADEC-2-YL)PROPYL)AMINO)CARBONYL)PHENYL)METHYL)AMINO)-2-OXOETHYL)- Rosai-Dorfman Disease	Memorial Sloan Kettering Cancer Center	Early P1	C (39)
1,4,7,10-TETRAAZACYCLODODECANE-1,4,7-TRIACETIC ACID, 10-(2-(((4-(((3-((2R,5S,8S,14R)-5-(3-((AMINOIMINOMETHYL)AMINO)PROPYL)-14-((4-HYDROXYPHENYL)METHYL)-1-METHYL-8-(2-NAPHTHALENYLMETHYL)-3,6,9,12,15-PENTAOXO-1,4,7,10,13-PENTAAZACYCLOPENTADEC-2-YL)PROPYL)AMINO)CARBONYL)PHENYL)METHYL)AMINO)-2-OXOETHYL)- Small Cell Lung Carcinoma (SCLC)	Institut Cancerologie de l'Ouest	Early P1	C (39)
177lu-dota-sna040 Advanced Solid Tumors (Such as Adenocarcinoma at the Gastroesophageal Junction)	SmartNuclide Biopharma	Early P1	C (39)
177lu-dota-sna040 Advanced Solid Tumors (Such as Cholangiocarcinoma)	SmartNuclide Biopharma	Early P1	C (39)
177lu-dota-sna040 Advanced Solid Tumors (Such as Gastric Cancer)	SmartNuclide Biopharma	Early P1	C (39)

Showing 76 to 100 of 1,583 assets

PreviousPage 4 of 64Next